Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
Launched by CARELON RESEARCH · Oct 27, 1999
Trial Information
Current as of March 16, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Approximately 7.5 percent of all acute myocardial infarctions which are diagnosed in an emergency room or in-hospital lead to cardiogenic shock and an in-hospital death rate of 70 to 80 percent, usually within one to two days of diagnosis of cardiogenic shock. The high death rate has not changed in the last two decades. Non-random clinical series and animal studies suggest that rapid revascularization following cardiogenic shock complicating acute myocardial infarction may substantially improve survival. However, the apparent benefit reported in the non-random clinic studies co...
Gender
ALL
Eligibility criteria
- • Men and women with myocardial infarction and cardiogenic shock.
Trial Officials
Lynn Sleeper
New England Research Institute, Inc.
About Carelon Research
Carelon Research is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on delivering high-quality clinical trials across various therapeutic areas, Carelon Research collaborates with healthcare professionals, institutions, and patients to ensure the integrity and efficacy of its studies. The organization is committed to ethical practices and compliance, fostering an environment of transparency and collaboration. By leveraging cutting-edge technology and a patient-centric approach, Carelon Research aims to accelerate the discovery of new therapies that enhance patient outcomes and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials